Abstract
data show that EBV deregulates KDM2B levels through an epigenetic mechanism and 48 provide evidence for a role of KDM2B in regulating virus and host cell gene expression, 49
warranting further investigations to assess the role of KDM2B in the process of EBV-50 mediated lymphomagenesis. 51 IMPORTANCE. In Africa, Epstein-Barr virus infection is associated with endemic Burkitt 52 lymphoma, a pediatric cancer. The molecular events leading to its development are poorly 53 understood compared to the sporadic Burkitt lymphoma. In a previous study, by analyzing 54 the DNA methylation changes in endemic compared to sporadic Burkitt lymphomas cell 55 lines, we identified several differential methylated genomic positions in proximity of genes 56 with a potential role in cancer, among them the KDM2B gene. KDM2B encodes a histone H3 57 demethylase already shown to be involved in some hematological disorders. However, 58
whether KDM2B plays a role in the development of Epstein-Barr virus-mediated lymphoma 59 has never been investigated before. In this study we show that Epstein-Barr virus deregulates 60 KDM2B expression and describe the underlying mechanisms. We also reveal a role of the 61 demethylase in controlling viral and B-cells genes expression, thus highlighting a novel 62 interaction between the virus and the cellular epigenome. 63
Introduction 64
Epstein Barr Virus (EBV) is a human gammaherpesvirus. More than 95% of the human 65 worldwide adult population is infected by EBV. After infection, EBV establishes a life-66 long latency, with often no adverse consequence for health. Despite its ubiquity, EBV 67 infection is also associated with many human cancers, among them endemic Burkitt's 68 lymphoma (eBL) the most common childhood cancer in equatorial Africa (1). This 69 malignancy has been associated with EBV infection more than 50 years ago, however to 70 date the exact mechanism by which the virus contributes in the eBL pathogenic process is 71 not fully understood. 72
Many studies have highlighted a key role of epigenetic deregulations in cell 73 transformation and cancer development. Increasing evidence argues that different viruses 74 may abrogate cellular defense systems by hijacking epigenetic mechanisms to deregulate 75 host cell gene expression program and modulate their own life cycle (2, 3). Our recent 76 study of the methylome profiles of sporadic-versus endemic-derived BL cell lines 77 revealed EBV infection-specific pattern of methylation, with aberrant methylation in 78 genes with a known role in lymphomagenesis, such as ID3, often found mutated in 79 sporadic BL (sBL) (4). We therefore hypothesized that a viral-driven mechanism is 80 responsible for modifying the epigenome of B-cells to facilitate the lymphomagenic 81 process, circumventing the need for mutations in lymphoma driver genes. Among the 82 genes differentially methylated in eBL compared to sBL, we identified the KDM2B gene, 83 which encodes a histone H3 demethylase known to target specific sites such as 84 trimethylated Lysine 4 (3me-K4) and di-methylated Lysine 36 (2me-K36). KDM2B sets 85 up the stage for DNA methylation and gene silencing by recruitment of the polycomb-1 86 proteins to un-methylated CpG regions (5) and plays a key role in somatic cells 87 reprogramming (6). It also represses the transcription of ribosomal RNA genes inhibiting 88 cell growth and proliferation (7). KDM2B has been identified as a putative tumor 89 suppressor by retroviral insertion analysis in mice (8). Low level of KDM2B expression 90 has been found in aggressive brain tumors, suggesting its potential role in cancer 91 development. Moreover, KDM2B plays a key role in hematopoietic cell development and 92 displays opposing roles in tumors of hematopoietic and lymphoid origins (9). While high 93 level of KDM2B expression has been observed in different hematological malignancies, 94 its depletion from hematopoietic cells has been reported to activate cell cycle and reduce 95 the activity of interferon and lymphoid-specific transcription factors, thereby contributing 96 to myeloid transformation (9). However, whether KDM2B affects EBV life cycle has 97 never been determined, nor its role in endemic BL has been assessed. Here, using in vitro 98
EBV-infection models, we aimed to assess whether the virus can alter the expression of 99 KDM2B by inducing its gene methylation. Finally we investigated how this event impact 100 on EBV infection and B-cells homeostasis. Overall, our data highlight a novel crosstalk 101 between EBV and the cellular epigenome, identify KDM2B as a master regulator of EBV 102 gene expression in addition to B-cell gene expression, suggesting a role for EBV-103 mediated KDM2B deregulation in the lymphomagenic process. 
Results

111
112
KDM2B is epigenetically silenced in EBV+ BL derived cell lines. 113
Our comparative analysis of the whole genome methylation profiles of a set of EBV (+) 114 and EBV (-) Burkitt's lymphoma derived cell lines (4), led to identification of two CpGs 115 (CpG 15695155 and 21423404) in an intragenic putative regulatory region of KDM2B 116 (Fig 1A) highly methylated in EBV (+) BL derived cells. To validate these data we 117 performed direct pyrosequencing on DNA extracted from 7 BL EBV (+) BL and 7 EBV 118 (-) BL derived cell lines and confirmed that KDM2B gene is hyper-methylated at CpG 119 15695155 and 21423404 in EBV (+) BL cell lines compared to EBV (-) BL cell lines 120 ( Figure 1B ). Next we asked whether these different patterns of methylation affect 121 KDM2B expression level. Four EBV (+) BL and 3 EBV (-) BL samples were analyzed 122 by immunohistochemistry for the KDM2B protein expression level. Three out of four 123 EBV (+) samples showed a weaker staining compared to the EBV (-) BLs, suggesting 124 that EBV infection induces a reduced expression of KDM2B protein in vivo (Fig 1C) . Of 125 note, the EBV (+) sample with stronger KDM2B staining, had a fewer amount of EBER 126 expressing cells, as shown by the EBER FISH (data not shown). We next assessed 127 whether silencing of KDM2B expression in EBV (+) BL cell lines was mediated by DNA 128 methylation. Treating 3 EBV (-) BL and 3 EBV (+) BL cell lines with the demethylation 129 agent 5-Aza-2′-deoxycytidine (Aza) for 48h led to a significant rescue of KDM2B 130 expression level in EBV (+) BL, whereas no noticeable changes in KDM2B mRNA 131 expression was observed in EBV (-) BL cells (Fig 1D) . In conclusion, our data show that 132 the specific CpG sites in the regulatory region of KDM2B are methylated in EBV (+) BL 133 compared to EBV (-) BL cell lines confirming our previous whole methylation profiling 134 data (4). Moreover, silencing of KDM2B expression appears to be a frequent event in 135 endemic BLs specimens and to be mediated by DNA methylation. These data indicate 136 that EBV may regulate KDM2B expression level by inducing methylation at a specific 137 regulatory region of the gene. 138
Infection of B cells with EBV leads to down-regulation of KDM2B levels. 139 140
To assess the ability of EBV to deregulate KDM2B expression level we infected B-cells 141 isolated from 4 independent donors with EBV and let the cells immortalize to generate 142 lymphoblastoid cell lines (LCLs). The expression level of KDM2B in these cell lines 143
were then compared to that in the parental counterparts by RT-qPCR. LCL showed 144 reduced expression level of KDM2B transcripts compared to primary B-cells (Fig 2A) , 145 highlighting a role of EBV infection in the regulation of KDM2B mRNA expression. To 146 evaluate whether downregulation of KDM2B in LCLs compared to primary B cells was 147 due to infection with EBV or occurred as a side effect of the immortalization process, we 148 monitored the changes in the expression level of KDM2B at different time points during 149 the process of in vitro EBV-mediated B cells immortalization. To this end, B-cells from 150 different donors were infected with EBV. Cells were harvested at 48h, 96h and 4 weeks 151 after infection, when LCLs were established, processed for RNA isolation and analyzed 152 by RT-qPCR for the expression level of KDM2B. Forty-eight hours after EBV infection 153 we could already observe a significant downregulation of KDM2B mRNA and protein 154 levels compared to the parental primary B-cells (Fig 2B-C (Fig 2D and E) , confirming the results obtained in EBV-infected primary B-cells. 163
To determine whether the reduced expression of KDM2B in EBV immortalized cells 164 could be due to an increase in DNA methylation, LCLs were treated with the 165 demethylating agent Aza and analyzed by RT-qPCR for the expression level of KDM2B. 166
Aza-treated LCLs showed increased expression level of KDM2B mRNA, compared to 167 their untreated counterpart, indicating that downregulation of KDM2B in EBV infected 168 cells is mediated by DNA methylation (Fig 2F) . As incorporation of Aza into the DNA 169 impedes its methylation by DNMTs (10), we hypothesized that EBV could contribute to 170 KDM2B silencing by increasing the recruitment of DNMT1 onto the KDM2B gene. 171
Indeed depletion of DNMT1 in LCLs by transfection of DNMT1 siRNA led to an 172 increase level of KDM2B mRNA expression (Fig 2G) . Moreover, ChIP experiments 173
showed an increased recruitment of DNMT1 onto the CpG site of the KDM2B gene in 174 RPMI cells infected with EBV (Fig 2 H) . 175
Taken together, these results indicate that EBV infection in B-cells leads to a reduced 176 expression of KDM2B. DNMT1-mediated methylation of KDM2B gene appears to play 177 a role in this event. 178
179
The oncogenic viral protein LMP1 induces the silencing of KDM2B 180
Next we asked whether LMP1, the main EBV oncoprotein, may play a role in the 181 deregulation of KDM2B expression. To this aim, we have generated RPMI cells stably 182 expressing LMP1. As a negative control, the cells were transduced with the empty 183 retroviral vector (pLNSX) (Fig. 3A) . As revealed by the RT-qPCR analysis, compared to 184 RPMI-pLXSN, RPMI-LMP1 cells display lower expression levels of KDM2B mRNA 185 and protein (Fig 3B-C) . Thus, LMP1 appears to play a role in EBV-mediated 186 downregulation of KDM2B expression. In addition, treating RPMI-LMP1 cells with Aza 187 led to a rescue of KDM2B RNA levels ( Fig 3D) . By contrast, no change in KDM2B 188 mRNA expression level was observed when treating RPMI-pLXSN cells with the DNA 189 demethylating agent. This was confirmed by pyrosequencing of the two CpG sites that 190 were previously identified as differentially methylated in EBV (+) BL cell lines (CpG 191 21423404 and CpG15695255). RPMI-LMP1 cells have higher levels of DNA 192 methylation at both CpG when compared to RPMI-pLXSN, even though the difference is 193 higher for the CpG 15695255 (Fig 3E) . 194 LMP1 activates respectively NF-kB and JNK pathway through its CTAR1 or CTAR2 195 domains. Therefore, to gain insights into the mechanism by which LMP1 deregulates 196 KDM2B expression we generated RPMI cells expressing LMP1 mutants, harboring 197 mutations on CTAR1 (mutant 3AAA), CTAR2 (mutant 378) or on both CTARs (mutant 198 3AAA/378) and having therefore hampered ability to activate NFB or JNK, or both 199 pathways. We then compared the ability of the different LMP1 mutants to deregulate 200 KDM2B. As shown in Figure 3F , mutant 378 retained the ability to downregulate the 201 KDM2B mRNA level with a similar efficiency as WT LMP1. By contrast, the 3AAA 202 mutant, as well as the double mutant, was unable to downregulate KDM2B mRNA levels 203 even though lower, KDM2B mRNA and protein level when compared to primary B-cells 275 (Fig 2 A-B and data not shown). Therefore KDM2B was overexpressed in LCLs by 276 ectopic expression of a HA-KDM2B. Forty-eight hours upon transfection, LCLs were 277 collected and processed for total protein and DNA/RNA extraction. Western blot analysis 278 showed increased KDM2B protein level (Fig. 5A ). Efficient expression of ectopic 279 KDM2B was also confirmed by RT-qPCR (Fig. 5B) . LCLs overexpressing KDM2B 280 carried a similar number of EBV genome copies compared to LCL transfected with the 281 control pCDNA vector (Fig. 5C ). We then analyzed the mRNA expression level of 282 different EBV transcripts by RT-qPCR. Ectopic KDM2B expression led to a significant 283 reduction of the mRNA expression level of all the analyzed EBV genes (Fig. 5D) . By 284 contrast, depletion of KDM2B from LCL by transfecting KDM2B siRNA (Fig. 5E-F ) led 285 to a significant increase in the expression of EBV genes, compared to the expression 286 level of the same genes in siRNA scrambled transfected LCL (Fig. 5H) . Removal of 287 KDM2B did not significantly affect EBV genome copy number (Fig. 5G) . Taken  288 together, these data indicate that KDM2B controls viral gene expression in latently 289 infected cells. 290
We next asked whether KDM2B could directly bind to EBV gene promoters to regulate 291 their expression. To this aim, purified primary B-cells, infected or mock infected with 292 EBV for 48h, as well as the corresponding LCLs, were formaldehyde-fixed and 293 processed for KDM2B Chromatin Immunoprecipitation (ChIP) (Fig 5I) . ChIP analysis 294
show that KDM2B can be detected on some EBV gene promoters at 48h post infection, 295 as well as in EBV-immortalized B cells. As expected, we did not detect KDM2B 296 recruitment on the promoter of the house keeping gene GAPDH, however we observed 297 an efficient KDM2B binding to a sequences located downstream of the transcription start 298 site of the rDNA repeated units 8 (H8), that was previously reported to be targeted by the 299 epigenetic enzyme (18). This data indicates that KDM2B is directly recruited on the EBV 300 gene promoters. To further assess the ability of KDM2B to be recruited onto the EBV 301 genome, B cells were EBV infected or not, collected and processed for Immuno-FISH 302 experiments. EBV DNA molecules were detected by fluorescence in situ hybridization 303 with a labeled probe directed against the BamHI W EBV genomic repeated region; 304 KDM2B was concomitantly detected by immunofluorescence by using an anti-KDM2B 305
antibody. In EBV infected B-cells, KDM2B patches partially overlapped or were found 306 in close proximity with the viral DNA (Fig 5J) , suggesting that the epigenetic enzyme is 307 recruited into or close to the viral genome early upon infection. Taken together, our data 308 demonstrate a role of KDM2B in controlling EBV gene expression. of hematopoietic cells (9). We then asked whether altered KDM2B expression could also 314 have an impact on the B-cell phenotype, in our experimental models. Louckes and LCLs 315 overexpressing KDM2B did not show altered proliferation ability, nor did they show 316 altered cell cycle or apoptotic profiles (data not shown). Therefore, to get further insight 317 on the impact of KDM2B deregulation on B-cells, we performed RNA expression chip 318 array in Louckes cells expressing increasing levels of KDM2B. Cellular genes whose 319 expression was significantly altered in the presence of increased expression level of 320 KDM2B ( Fig 6A) were identified by bioinformatics analysis. In line with its known 321 function as demethylase of H3 K4, KDM2B altered gene set were enriched of H3 K4-322 me1 (Fig 6B) . Among the genes significantly deregulated in the presence of altered 323 KDM2B expression level, some played a role in immunity (Fig 6C) . Our analysis 324 revealed that KDM2B overexpression was associated with deregulated expression of 325 genes involved in the TNFR2 pathway (Fig 6C) . Interestingly, this pathway is important 326 for the transition of B-cells from the germinative centre to resting memory B-cells (19) . 327
Moreover, TNFR2 pathway mediates specific TNF effects and is an important mediator 328 of cell antiviral response (9). Deregulated expression of genes within this pathway were 329 confirmed and validated by RT-qPCR (Fig 6D) . Taken together, these data indicate that 330 KDM2B plays a role in B-cells differentiation and regulation of the TNF pathway, often 331 altered during the lymphomagenic process. 332
333
Discussion 334
In this study we show that a regulatory region within the gene encoding for KDM2B is more 335 methylated in EBV (+) BL compared to EBV (-) BL, confirming data from our previous study 336 aiming to characterize the whole epigenetic profile of a set of BL derived cell lines of 337 endemic or sporadic origins. This region is found methylated in certain cancer derived cell 338 lines (ENCODE DNA Methylation Tracks; CpG Methylation by Methyl 450K Bead Arrays 339 from ENCODE/HAIB; UCSC genome browser). Furthermore, KDM2B levels appear to be 340 deregulated in cancer of hematological origins (9). We therefore asked whether increased 341 methylation of KDM2B gene in eBL was mediated by EBV to deregulate the histones 342 modifier intracellular levels and promote EBV-mediated lymphomagenesis. EBV led to a rapid silencing of KDM2B expression. Low KDM2B mRNA level at early 360 stages of EBV infection of primary B cells was also observed in a data set from a RNA 361 expression profiling performed in an independent study (Manet E. personal communication). 362
By using different means we also show that downregulation of KDM2B expression in EBV 363 infected cells is mediated by DNMT1 recruitment onto its gene and by DNA methylation. It 364 has already been reported that EBV can alter DNMT1 activity through its viral proteins (24). 365
In particular Chia-Lung Tsa and colleagues showed that LMP1 activates DNMT1 activity 366 (12) and this event requires activation of the JNK/AP1 pathway. 367
Here we show that cells stably expressing LMP1 display lower levels of KDM2B. The ability 368 of LMP1 to downregulate KDM2B depends upon its NF-kB activity, as shown by using an 369 LMP1 molecule mutated at its NF-kB activating domain, and by blocking NF-kB pathway via 370 a specific chemical inhibitor. By contrast, the use of a LMP1 mutant lacking JNK pathway 371 activation potential or a specific JNK inhibitor had no effect on KDM2B mRNA expression 372 level. Moreover, our ChIP experiments showed that expression of LMP1 in the EBV (-) 373 RPMI cells is able to trigger DNMT1 recruitment on the KDM2B gene. The finding that the 374 recruitment of DNMT1 on the KDM2B gene can be hampered by treating LMP1-RPMI cells 375 with the IκBα kinase inhibitor, further confirms its dependence on LMP1 ability to induce 376 NF-kB pathway. Recent published data showed that HPV16 E6/E7 transforming proteins 377 inhibit the expression of mir146-5p, known to target KDM2B transcript, which results in the 378 increase of KDM2B expression level, in HPV16 infected cells. In contrast to E6/E7, EBV 379 transforming protein LMP1 induces mir146-5p, via its ability to activate NF-kB (25). This 380 event could contribute to the reduction of KDM2B mRNA level in cells expressing LMP1. It 381 is therefore possible that LMP1 uses alternative mechanisms to target KDM2B: (i) increasing 382 its DNMT1-mediated gene methylation and (ii) controlling its mRNA expression level by a 383 specific miRNA. Further studies are needed to assess the contributions of deregulated mir146-384 5p levels in the events described here. 385
Our and other laboratories' previous studies showed that EBV can modulate the level and the 386 activity of different epigenetic enzymes (14, 15, 26), which in turn play a role in regulating 387 viral genes expression. One example is provided by EZH2, whose intracellular expression 388 level is induced in B-cells by EBV infection in a LMP1-dependent manner (27). EZH2, in 389 turn, is recruited to the viral genome where it participates to the establishment and 390 maintenance of EBV latency by methylating the H3 K27 in proximity to the BZLF1 and 391 performed in duplicate and the mRNA levels obtained were normalized on the average 467 mRNA levels of three housekeeping genes (β-globine, β-actine, GAPDH), measured in 468 the same samples. In order to measure EBV genome copy number per cell, total DNA 469 was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen) and measured by 470
BRFL1 promoters (16). Our observation that EBV infection alters KDM2B expression
NanoDrop. Similar amounts of DNA were used as a template for the Taqman PCR, 471 performed according to protocol described in Accardi et al. (29) . The PCR primer 472 sequences are indicated in Table 1 . 473 474 Kdm2b overexpression and Gene-expression silencing. The KDM2B coding region was 475 cloned into pCDNA3 vector in frame with an HA-tag at the N terminus. LCLs ( 1×10 7 ) 476 and Louckes (5x10 6 ) were transfected with growing concentration of HA-KDM2B 477 pCDNA3 (0,5-1,0-1,5ug) or with pCDNA3 vector as control by electroporation using 478 the Neon Transfection System (10 µl tips) (pulse voltage, 1350V; pulse width, 479 30ms,pulse number 1). At 24h post-transfection, the cells were collected and processed 480 for RNA/DNA extraction. Gene silencing of KDM2B was performed using KDM2B 481 Table 1 . 528
Whole Genome Expression Analysis. Differential expression analysis was performed 529 using Human HT-12 Expression BeadChips (Illumina) as previously described (4, 29) . 530
Probes with p value < 0.01, false discovery rate (FDR) < 0.05 and a fold-change of at 531 least 1.5 were considered differentially expressed. analyzed for the levels of the indicated protein by western blot (E). F. LCL were cultured 588 for 96h in presence of DMSO or 5-Aza-2′-deoxycytidine (AZA) used as in Figure 1C . 589 Cells were then collected and the extracted mRNA were analyzed for the levels of 590 KDM2B. G. LCL were transfected as explained in Methods section with stabilized 591 DNMT1 siRNA. Four days after transfection cells were collected and analyzed for the 592 levels of mRNA of DNMT1 (upper panel) and KDM2B (lower panel). H RPMI cells 593 infected as for figure 2D-E were fixed and processed for ChIP with a DNMT1 antibody 594 and IgG as negative control. The eluted DNA was analysed by qPCR with primers 595 flanking the cg15695155 and cg21423404 (primer sequences described in Table 1 ). 596 as an empty control. Cells were collected 24h after transfection and processed for 646 RNA/DNA and total protein extraction. Total protein extracts were analysed by western 647 blot for the indicated proteins (A). KDM2B mRNA levels were assessed by qPCR (B). 648 DNA samples were analyzed by Taqman PCR to assess the number of EBV genome 649 copies per cell (C) The mRNA expression levels of EBV early and late genes were 650 assessed by qPCR (D). E-H LCL transfected with KDM2B siRNA and scr siRNA as 651 control were collected at 48h post transfection, processed and analysed for the levels of 652 KDM2B protein (E) and transcript (F). DNA and cDNA samples were analysed 653 respectively for the EBV DNA copy number by Taqman PCR (G) and for the expression 654 levels of the EBV genes by qPCR (H). I. Primary B cells were infected with EBV for 48h 655 or let immortalized until they generate LCL. Not infected B cells, B cells EBV infected 656 for 48 and LCLs were formaldehyde fixed and processed for ChIP using a KDM2B 657 antibody. The eluted DNA was analyzed by qPCR with primers designed on different 658 EBV gene promoters. As negative controls the promoter of the GAPDH promoter was 659 also amplified, the recruitment of KDM2B to its known cellular gene target, H8 was also 660 assessed. J. Louckes cells infected or not with EBV (no GFP) were fixed on glass slides 661 and processed for immuno-FISH. EBV DNA was detected by FISH and KDM2B by 662
Immunofluorescence. EBV/KDM2B overlapping signals are shown in the merge fields as 663 yellow dots. 664 
